Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Biogen Halts Tysabri Development in Stroke as Study Fails

Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

    Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat

    Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

      Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up

      Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

        What's in the Cards for Biogen (BIIB) This Earnings Season?

        On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

          Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

          Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

            Arpita Dutt headshot

            3 Pharma and Biotech Stocks to Watch Out for in 2018

            Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

              Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

              Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

                Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs

                Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

                  Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                    Biogen's Alzheimer's Drug Misses Goal in Interim Analysis

                    Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.

                      The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                      The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                        Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

                        Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy

                          A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

                            Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

                              Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

                              The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

                                While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

                                  Mark Vickery headshot

                                  Top Research Reports for Amazon, AbbVie & Biogen

                                  Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), AbbVie (ABBV) and Biogen (BIIB).

                                    Biogen Acquires Worldwide License for Alkermes' MS Candidate

                                    Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

                                      Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil

                                      Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil

                                        Tracey Ryniec headshot

                                        Should You Buy the Beaten Down Blue-Chip Stocks?

                                        Just because a stock plunges to multi-year lows, that doesn't mean it's a value stock.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

                                          FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

                                            PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

                                            PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

                                              Is a Beat in Store for Ionis (IONS) This Earnings Season?

                                              Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

                                                Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y

                                                Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.

                                                  Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up

                                                  Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.